December 14, 2022
mRNA Vaccines: From Discovery to Platform | December 14, 2022 15:00 - 17:00 EST
We have three significant speakers lined up for an in-depth overview of mRNA vaccines and therapeutics, followed by a panel discussion with live audience participation. You can join from anywhere in the world and participate in real time about this important topic. Registration will close December 12, 2022.
Most people hadn’t heard of mRNA before COVID. Since their introduction mRNA vaccines have been recognized as a technology which is readily adaptable to different diseases and infections, as well as to rapidly evolving viral variants. Their structure and manufacture resembles something closer to a synthetic small molecule than a biologically generated antigen while protection against historical and new pathogens is just an insertion change away from being a vaccine candidate. This DC Discussion Group session will be dedicated to the discovery and introduction of mRNA to the repertoire of live virus, protein based, polysaccharide, and other genetically based immunogens, and will highlight the opportunity to use platform thinking to facilitate the development and manufacture of vaccine of the future.
The Path to Success for mRNA Vaccines | Sarita Acharya, US Pharmacopeia.
Ensuring Quality and Safety of mRNA Vaccines Today and Tomorrow | Jeff Ulmer, formerly GlaxoSmithKline.
Capping and Poly(A) Tail Analysis for mRNA Vaccine Product Development | Qi Zeng, GlaxoSmithKline.